Jazz Pharmaceuticals

Phone: +353353.1.634.7800

E-mail: corporateaffairsmediainfo@jazzpharma.com

Web: https://www.jazzpharma.com

Type	Public company
Traded as	Nasdaq: JAZZ S&P 400 component
Industry	Biotechnology Pharmaceutical
Predecessor	Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
Founded	March 2005 (2005-03) in California, U.S.
Headquarters	Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland
Area served	Worldwide
Key people	Bruce C. Cozadd (Chairman & CEO)
Products	Pharmaceutical drugs
Brands	Xyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt Vyxeos
Revenue	US$1.618 billion (2017)
Operating income	US$528.8 million (2017)
Net income	US$487.8 million (2017)
Total assets	US$5.123 billion (2017)
Total equity	US$2.713 billion (2017)
Number of employees	~1,210 (February 2018)
Website	jazzpharma.com

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Through continued investment in an evolving and growing research and development focus, we seek solutions for rare or complex diseases, and ensure those solutions are available for the often-overlooked patients who need them. Our approach has allowed us to shepherd new medicines to market – from late-stage discovery through clinical development and regulatory approval. All of these advancements are a reflection of our continued investment in an evolving and growing research and development focus.

For detailed contact information visit location pages below.